Partner News | Published: Thursday, April 9, 2026
MedAxiom, the cardiovascular community’s premier source for organizational performance solutions, announced a new industry partnership with Johnson & Johnson MedTech, the global leader in heart recovery with Impella heart pumps for patients with advanced heart disease.
The Impella heart pump platform includes a family of microaxial heart pumps that are inserted percutaneously to temporarily support cardiac function. By taking over the heart’s pumping activity, Impella enables the heart to rest and recover while maintaining systemic perfusion, supporting care teams in the management of high-risk percutaneous coronary intervention (PCI) and cardiogenic shock.
“We are pleased to welcome Johnson & Johnson MedTech to the MedAxiom community,” said Joe Sasson, PhD, executive vice president of Ventures and chief commercial officer at MedAxiom. “Their experience in mechanical circulatory support through the Impella platform provides a unique perspective for MedAxiom members. Their knowledge and experience will help cardiovascular leaders better understand how these technologies can be integrated into care pathways to support patients with complex cardiac conditions.”
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.
